Menu
Search
|

Menu

Close
X

Regulus Therapeutics Inc RGLS.OQ (NASDAQ Stock Exchange Capital Market)

0.83 USD
-- (--)
As of Sep 17
Previous Close 0.83
Open --
Volume --
3m Avg Volume 31,493
Today’s High --
Today’s Low --
52 Week High 3.14
52 Week Low 0.54
Shares Outstanding (mil) 20.77
Market Capitalization (mil) 14.12
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY19
7
FY18
0
FY17
0
FY16
1
EPS (USD)
FY19
-0.314
FY18
-5.594
FY17
-9.010
FY16
-18.596
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.85
Price to Sales (TTM)
vs sector
2.07
7.90
Price to Book (MRQ)
vs sector
--
4.38
Price to Cash Flow (TTM)
vs sector
--
23.70
Total Debt to Equity (MRQ)
vs sector
--
17.64
LT Debt to Equity (MRQ)
vs sector
--
12.61
Return on Investment (TTM)
vs sector
-274.55
12.69
Return on Equity (TTM)
vs sector
-427.71
17.13

EXECUTIVE LEADERSHIP

Stelios Papadopoulos
Chairman of the Board, Since 2013
Salary: --
Bonus: --
Joseph Hagan
President, Chief Executive Officer, Interim Principal Financial Officer, Director, Since 2019
Salary: --
Bonus: --
Daniel Chevallard
, Since
Salary: --
Bonus: --
Daniel Penksa
Principal Accounting Officer, Controller, Since 2019
Salary: --
Bonus: --
Kathryn Collier
Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

10628 Science Center Dr Ste 100
SAN DIEGO   CA   92121-1128

Phone: +1858.2026300

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

SPONSORED STORIES